- Continue Shopping
- Your Cart is Empty
Avadim Technologies Named to the Inc. 500 List of Fastest-Growing Private Companies in America
Avadim Ranks No. 234 on the 2016 Inc. 500 List with Three-Year Sales Growth of 1,675%
Asheville, NC (August 17, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions, and the associated reactive tissue, today announced that Inc. Magazine has recognized the Company as one of the fastest growing private companies in America. Inc. Magazine today ranked Avadim # 234 on its 2016 Inc. 500 List, an exclusive ranking of the nation's fastest-growing private companies.
The achievement has put Avadim in an elite group of companies who have previously been named to the Inc. 500 including Microsoft, Under Armour, Intuit, GoPro, Oracle, Timberland, Clif Bar, Patagonia, Zappos and many other well-known names gained early exposure as members of the Inc. 500. In addition to Avadim, the 2016 Inc. 500 list includes Dollar Shave Club, Square, ipsy, and Yeti Cooler.
Stephen Woody, Avadim Chairman and CEO, stated, “We are honored to be selected to join the respected list of the fastest-growing 500 private companies in America and we look forward to our continued growth and innovation. This accomplishment is a testament to the team, business model, strategy, and proprietary technology we have in place at Avadim. Going forward we will work closely with our customers and partners as we continue to address the gaps in global health including infection, neuromuscular disorders and wound care.”
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803
Investor Relations:
Capital Markets Group, LLC
914.669.0222
[email protected]
www.CapMarketsGroup.com
Avadim Technologies Launches New [pH]UEL 5.0™ Website
Avadim Introduces Breakthrough Topical Anti-Spasmodic Sports Medicine Technology
Asheville, NC (June 23, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that [pH]UEL 5.0™, its non-toxic topical anti-spasmodic with magnesium, launched its new website https://phuel5.com.
In conjunction with the new website, [pH]UEL 5.0™ will be showcased at the 67th National Athletic Trainers Association (“NATA”) Clinical Symposia & AT Expo, in Baltimore, MD on June 22-25, 2016. According to NATA, this year’s Clinical Symposia will bring more athletic trainers under one roof than any other tradeshow.
Among the many website enhancements, you will notice a clean, modern design with easy navigation and helpful tools. The purpose of the website is to provide a useful, informative portal regarding [pH]UEL 5.0™’s technology, safety and commitment to scientific and medical research. For our customers including teams, organizations and individuals, the Company has unveiled an e-commerce platform to purchase [pH]UEL 5.0™ quickly and easily through the click of a button.
Additionally, [pH]UEL 5.0™ has added its brand ambassador campaign launching Patrick Peterson, 5-time NFL pro-bowler for the NFL’s Arizona Cardinals and the visual representation of [pH]uel5.0™ physiologic mechanism and benefits. Patrick’s likeness, reputation and personal belief in the product are clearly and visually represented. The creative theme completed by Common Thread Collective will serve to capture mental access of athletes and sports medicine influencers both nationwide and internationally.
Stephen Woody, Chairman and CEO, stated, “As part of our commitment to continuously improve our service offering to our customers, we are delighted to unveil our new website. We are excited to bring our customers a website that provides the latest and best information about all things [pH]UEL 5.0™. As with our other Pathogenesis Based Therapies, we are excited about [pH]UEL 5.0™’s ability to fill this major global gap in sports medicine.”
[pH]UEL 5.0™ has become the Official Multi-Performance Technology Partner of the Big South Conference including all eleven institutions as well as their Athletic Directors, Athletic Trainers and Coaches. [pH]UEL 5.0™’s patented therapies and protocols are being utilized and evaluated by over 500 professional, university and high school athletic teams through the United States including the St. Louis Blues, Washington Capital, University of Florida and Duke.
[pH]UEL 5.0™ has been clinically formulated to lower the pH of the skin. Scientific evidence suggests that maintaining and lowering the pH of the body’s largest organ, the skin, increases oxygen availability and uptake. Oxygen availability is a cornerstone for recovery and optimal performance.
Sports medicine continues to search for safe, effective and non-systemic solutions for Exercise-Associated Muscle Cramps (“EAMC”) and associated tightness and soreness, that have been shown to increase the risk of athletic injury and prevent optimal performance. [pH]UEL 5.0™’s patented low pH formulation has been shown to significantly reduce the incidence of EMAC and associated symptoms in the elite athlete.
For more information on [pH]UEL 5.0™ call us today at 877-677-2723 or email us at [email protected].
About [pH]UEL 5.0™:
[pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic arenas. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
For more information on Avadim, visit www.avadimtechnologies.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Investor Relations:
Capital Markets Group, LLC
914.669.0222
[email protected]
www.CapMarketsGroup.com
Avadim Technologies Welcomes Five-Time Pro-Bowler, Patrick Peterson, as Athlete Ambassador for [pH]UEL 5.0™
Asheville, NC (June 1, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company and manufacturer of the [pH]UEL 5.0™ Muscle Science System (“[pH]UEL 5.0™”), welcomes Patrick Peterson, five-time Pro Bowl cornerback for the NFL’s Arizona Cardinals as an athlete ambassador for the innovative topical muscle therapy products.
[pH]UEL 5.0™’s patented skin care system provides a breakthrough solution that supports muscle performance by optimizing the skin’s outermost layer, the stratum corneum.
“Avadim is pioneering the way for skin and muscle science in sports medicine,” said Peterson. “And to have them bring that expertise and innovation to a sports performance product like [pH]UEL 5.0™, is something truly special that I knew I wanted to be involved with. These products are transformational in every sense of the word.”
No stranger to wear and tear on his body, Peterson made history this year, joining three Hall of Famers as the only players chosen for five NFL Pro Bowls before reaching the age of 26. He has earned All-Pro honors as both a cornerback and kick returner.
“We are thrilled to announce Patrick Peterson (‘P2’) as the initial spokesperson for our [pH]UEL 5.0™ product. Athletes experience maximum impact on their muscles and have minimal recovery time to bounce back,” said Steve Woody, Chairman and CEO of Avadim. “Patrick embodies that truth, so it was a natural fit to have such a decorated and talented athlete like him join our family. [pH]UEL 5.0™ has been a ‘well kept secret,’ but that’s about to change. We’re confident that adding P2 will be a game changer for us.”
About [pH]UEL 5.0™:
[pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic space. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life science solutions based on Pathogenesis Based Therapies (“PBTs”) that work to optimize the stratum corneum, integumentary functions, and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within the three series of therapies for infection prevention, neuromuscular disorders, and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic, and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
About Patrick Peterson:
Patrick Peterson plays cornerback for the Arizona Cardinals of the National Football League. He was a first-round draft pick for the Cardinals in 2011, and recently signed a five-year extension of his contract to play with them through 2020. He has been voted into five straight Pro Bowls and is widely considered to be one of the league’s very best.
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Justin Niefer, Director of Sales & Marketing
828.251.7111 Office
770.846.8507 Cell
Avadim Technologies Inc.
81 Thompson Street
Asheville, NC 28803
www.avadimtechnologies.com
Investor Relations:
Capital Markets Group, LLC
914.669.0222
[email protected]
www.CapMarketsGroup.com
Avadim Technologies Launches its New [pH]UEL 5.0™ Sports Medicine Technology at the 67th National Athletic Trainers Association Clinical Symposia & AT Expo, in Baltimore, MD June 22-25, 2016
Avadim to Introduce Breakthrough Topical Anti-Spasmodic Sports Medicine Technology
Asheville, NC (May 24, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that [pH]UEL 5.0™, its non-toxic topical anti-spasmodic, will be showcased at the 67th National Athletic Trainers Association (“NATA”) Clinical Symposia & AT Expo, in Baltimore, MD on June 22-25, 2016.
According to NATA, this year’s Clinical Symposia will bring more athletic trainers under one roof than any other tradeshow. It is the world’s premier exhibition in sports medicine, with over 350 exhibitors and thousands of athletic trainers converging for a 3-day marketplace of products, education and services to outfit training facilities.
Stephen Woody, Chairman and CEO of Avadim, stated, “Sports medicine continues to search for safe, effective and non-systemic solutions for Exercise-Associated Muscle Cramps (“EMAC”) and associated tightness and soreness, that have been shown to increase the risk of athletic injury and prevent optimal performance. [pH]UEL 5.0’s™ patented low pH formulation has been shown to significantly reduce the incidence of EMAC and associated symptoms in the elite athlete.”
Mr. Woody continued, “Currently, our [pH]UEL 5.0’s™ patented therapies and protocols are being utilized and evaluated by over 500 professional, university and high school athletic teams throughout the United States including the St. Louis Blues, Washington Capitals, Tampa Bay Rays, University of Florida, Florida State, and Duke. As with our other Pathogenesis Based Therapies, we are excited about [pH]UEL 5.0’s ability to fill this major global gap in sports medicine.”
Scientific evidence suggests that maintaining and lowering the pH of the body’s largest organ, the skin, increases oxygen availability and uptake. Oxygen availability is a cornerstone for recovery and optimal performance. [pH]UEL 5.0 has been clinically formulated to lower the pH of the skin.
The NATA Clinical Symposia & AT Expo will be held at Baltimore Convention Center in Baltimore, MD on June 22-25, 2016. Athletic trainers are encouraged to visit [pH]UEL 5.0 at booth number 5113.
About [pH]UEL 5.0™:
[pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic arenas. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
For more information on Avadim, visit www.avadimtechnologies.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Investor Relations:
Capital Markets Group, LLC
914.669.0222
[email protected]
www.CapMarketsGroup.com
Avadim Technologies’ Sports Medicine Division Announces Strategic Partnership with the Big South Conference
Asheville, NC (May 12, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue for the outer layer of the skin, announced today a partnership with the Big South Conference. Avadim will provide athletes with their proprietary [pH]UEL 5.0™ product.
[pH]UEL 5.0™ is now the Official Multi-Performance Technology Partner of the Big South Conference, featuring a relationship with all eleven institutions and their Athletic Directors, Athletic Trainers and Coaches. [pH]UEL 5.0 will offer their topical muscle therapy products for the conference’s wide range of men’s and women’s sports and also integrate Avadim’s flagship clinical product, Theraworx, ™ into the locker rooms and athletic facilities to support and bolster every school’s infection prevention and wound care efforts for their athletes.
“The Avadim Sports Medicine Division is proud to be the Official Multi-Performance Technology Partner of the Big South Conference,” said Justin Niefer, [pH]UEL 5.0™ National Sales and Marketing Director. “Collegiate athletics continues to be a target market for our topical therapies providing athletes with the enhanced protection and recovery properties to enable their best performance. We look forward to a long and mutual beneficial relationship with the Big South and other NCAA athletic conferences.”
In addition to offering [pH]UEL 5.0 and Theraworx™ products to every team in the conference, the Avadim Sports Medicine Division will have an extensive educational and brand platform, including:
- Endorsement letter from the Big South Conference Commissioner that will be distributed to all pertinent decision makers on every campus announcing the partnership;
- Presenting at the Athletic Trainers’ Meeting in May and Annual Coaches’ Meetings held at the Conference office in Charlotte, North Carolina throughout the year;
- Presenting Sponsor of the Big South Conference Football and Basketball Media Days; and,
- Recognition on BigSouthSports.com, the official website of the Big South Conference.
“We thank [pH]UEL 5.0™ for its support of the Big South Conference,” stated Big South Commissioner, Kyle B. Kallander, who is in his 20th year as Big South Conference Commissioner. “Partnering with a company like [pH]UEL 5.0™ is very meaningful to the Conference and it aligns with our Core Values of Student-Athlete Welfare and Athletic Excellence.”
About [pH]UEL 5.0™: [pH]UEL 5.0™, a division of Avadim Technologies Inc., is committed to making a difference by bringing highly differentiated technologies into the health and athletic arenas. [pH]UEL 5.0™ is a topical technology, formulated for the most difficult muscle integrity issues including muscle performance, muscle tightness, muscle recovery, muscle cramps, and flexibility. For more information, visit www.phuel5.com
About Avadim Technologies, Inc.: Avadim Technologies, Inc. is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health. For more information, visitavadimtechnologies.com
About The Big South Conference (www.BigSouthSports.com): Founded in 1983, the Big South Conference has matured into a competitive leader in college athletics, actively pursuing excellence on the field of play and in the classroom. For more than 30 years, the League’s growing presence as an NCAA Division I athletic conference is evident by athletic accomplishments on the national stage, innovative marketing and media partnerships, increased television packages and quality athletic competition while intentionally fostering the academic, personal, social, athletic and leadership development of its student-athletes. Comprised of 11 member institutions sharing a common geographic region and similar academic values and purposes, the Big South Conference’s institutions — Campbell University, Charleston Southern University, Coastal Carolina University, Gardner-Webb University, High Point University, Liberty University, Longwood University, Presbyterian College, Radford University, UNC Asheville and Winthrop University — have a remarkable history of achievement through the League’s 19 championship sports in addition to the academic success of its more than 4,000 student-athletes. The Big South Conference: Developing Leaders Through Athletics.
Avadim Technologies Inc. Contacts:
Joe McGuire
Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann
President
828.251.7111 Office
904.251.4910 Cell
Investor Relations
Capital Markets Group, LLC
Alan Sheinwald or Valter Pinto
PH: (914) 669-0222